There has been great progress in treatment, but for most blood cancers, there is no cure and better therapies are needed. In this symposium, new and evolving treatment strategies will be discussed, including how the heterogeneous nature of blood cancers dictates treatment and prognosis, the role of clinical trials, and the evolving role of CAR T-cell therapy. Cases will focus on acute myeloid leukemia (AML) and on diffuse large B-cell lymphoma (DLBCL).
Sponsored by The Leukemia & Lymphoma Society and supported by educational grants from Kite Pharma, Inc. and Stemline Therapeutics, Inc.
